ASCO GU 2025

Milestones of ADT and ARPI treatment in the metastastic prostate cancer

What's the role of Enzalutamide in radioligand therapy?

Combining ARPi with PARPi - discussing final OS of TALAPRO-2

Testosterone Recovery

ARPI for which patients?

Mevrometostat + Enza: New option for mCRPC

Local radiotherapy of oligoprogressive mCRPC

OS in the TALAPRO-2 trial

Phase 2 Mevrometostat

Who benefits most from ARPIs?

ENZA-p showed OS benefit and improvement in QoL parameters

Fish-oil supplement for pts on active surveillance

Radical Prostatectomy VS RT in HRPC

Improved Survival with Enzalutamide + Lutetium

Hypo-gonadism bad for survival?

Final OS analyses

Mevrometostat - a new EZH2 inhibitor in mCRPC

Testosterone Recovery after ADT and OS

Final OS data for TALA + Enza

MDT in OMPC

Radiation vs surgery in high risk prostate cancer

Durvalumab in UTUC

Darolutamide + ADT reduces risk of progression or death by 46 % in mHSPC

Darolutamide + ADT and Doetaxel improves survivas in mHSPC across age groups

Oligometastatik PCa da MDT

Enza+Lu ile artmis sagkalim

Hangi hastalarda ADT+ARPI

Yuksek risk PCa da RP vs RT

UTUC de Neoadj. Durvalumab+Kemo

Testosteron Geri Gelisi ve Sagkalim

New data but no new conclusion

KIM-1 - The most interesting biomarker for RCC?

Exciting new substances - but don't over-estimate phase 1 data

Triplet combination in RCC - there's no free lunch with VEGFR

New data nccRCC

KIM-1 in CheckMate 214

AVION trial at mRCC

KIM-1 in mRCC

Prognostic and predictive biomarkers in mRCC: Looking for the holy grail

Advanced Renal Cell Cancer: Adding more drugs does not translate in greater benefit

New agents / new mode of actions

Firstline Update Kidney Cancer

Proactive coaching of patients with TKI +/- IO therapy

Casdatifan in refracting RCC

Biomarcadores prognósticos y predictivos en el CCRm: en busca del Santo Grial

Cáncer de células renales avanzado: añadir más fármacos no se traduce en un mayor beneficio

New data, but no new insights for adjuvant treatment of high-risk MIBC patients

Exploratory analyses of pCR in NIAGARA: who benefits most from perioperative Durvalumab?

Neoadjuvant chemo-immunotherapy in UTUC: new evidence for a challenging indication

Reassuring data on established ADCs and new insights in novel ADCs for urothelial cancer

ADC + ICI - The future for MIBC?

HER2 - new marker for bladder preservation

Sacituzumab Tirumotecan shows promising antitumor activity in aUC after platinum-based therapy

ASCO GU 25 - Summary: Urothelial Cancer

Preliminary results of neoadjuvant chemoimmunotherapy in UTUC

Nivo adjuvant in MIBC - a new standard

Updates neo/adjuvant therapy in MIBC

New FGFR3 inhibitor

A possible new standard for mUC

EV-Pembro continues to be the standard for mTCC

Adjuvant Nivo - independent from previous therapy

Bladder-sparing approaches - are we there yet?

New drugs in mUC: The active field of ADCs

The role of ctDNA in bladder cancer

Durvalumab + Platinum-based chemotherapy shows promising efficacy and safety in high-grade UTUC

Neoadjuvant treatment for UTUC

Promising combination for perioperative setting

Phase 2 Mevrometastat

Nuevos fármacos en mUC: El campo activo de las ADCs

Promising combination for perioperative setting

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Testicular cancer: Reinventing the wheel

RPLND in metastatic Seminoma

Metastatik seminomda Primer RPLND

Cáncer de testículo: reinventar la rueda